Special Issue "HDAC Inhibitors 2014"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: 15 October 2014
Prof. Dr. David T. Dexter
Parkinson’s Disease Research Group, Department of Cellular and Molecular Neuroscience, Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College London, London, UK
Interests: mechanisms of cell death; neuroprotection in Parkinson's disease
The journal “Pharmaceuticals” is planning to publish a special issue covering the topic “HDAC Inhibitors” and I am cordially inviting you to contribute an article to this volume.
Histone deacetylases (HDACs) are a group of enzymes capable of catalyzing the hydrolysis of N-acetyl lysine residues of histones which package chromosomal DNA. This causes the condensation or more tightly coiling of DNA around the histones leading the repression of DNA transcription. Therefore HDACs play an important role in mediating gene expression and cell proliferation. To date, 18 human HDAC isoforms have been characterised: based on their sequence homologies and co-factor dependencies they have been phylogenetically categorised into 4 main classes: class I, II (a and b), III and IV. HDAC inhibitors (HDACIs) have not only shown promise as antiparasitic, antineurodegenerative, antirheumatologic agents and immunosuppressant, but also as potent anticancer agents. This special issue invites original research articles, including review articles, on the pharmacology, biological effects, mechanisms of action and the clinical development of HDACIs for a variety of diseases.
Prof. Dr. David T Dexter
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
- histone deacetylase inhibitors (HDACIs)
- epigenetic modifications
- DNA transcription
- anti-inflammatory/immune modulation, anticancer
Review: Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
Pharmaceuticals 2014, 7(6), 634-661; doi:10.3390/ph7060634
Received: 15 January 2014; in revised form: 8 May 2014 / Accepted: 12 May 2014 / Published: 26 May 2014| PDF Full-text (401 KB) | HTML Full-text | XML Full-text
Last update: 6 May 2014